Table 3.
Association between the patients' characteristics and pCR.
| Characteristic | pCR | P value | |
|---|---|---|---|
| Yes | No | ||
| Median age, years (minimum–maximum) | 49.5 (23.5–77.7) | 47.8 (22.0–83.5) | 0.694a |
| Menopausal status, n (%) | 0.903b | ||
| Premenopausal | 54 (50.5) | 325 (51.1) | |
| Postmenopausal | 53 (49.5) | 311 (48.9) | |
| Clinical T stage, n (%) | 0.019b | ||
| T1/2 | 86 (81.9) | 432 (70.8) | |
| T3/4 | 19 (18.1) | 178 (29.2) | |
| Clinical Node status, n (%) | 0.681b | ||
| Negative | 39 (42.0) | 240 (39.0) | |
| Positive | 67 (58.0) | 377 (61.0) | |
| NLR, n (%) | 0.015b | ||
| Low | 74 (74.7) | 308 (61.8) | |
| High | 25 (25.3) | 190 (38.2) | |
| MLR, n (%) | 0.001b | ||
| Low | 63 (63.6) | 229 (46.0) | |
| High | 36 (36.4) | 269 (54.0) | |
| PLR, n (%) | 0.001b | ||
| Low | 72 (72.7) | 275 (55.2) | |
| High | 27 (27.3) | 223 (44.8) | |
| PIV, n (%) | < 0.001b | ||
| Low | 81 (81.8) | 270 (54.2) | |
| High | 18 (18.2) | 228 (45.8) | |
| ER status, n (%) | < 0.001b | ||
| Negative | 63 (60.6) | 121 (21.5) | |
| Positive | 41 (39.4) | 443 (78.5) | |
| HER-2 status, n (%) | < 0.001b | ||
| Negative | 55 (52.9) | 453 (80.3) | |
| Positive | 49 (47.1) | 111 (19.7) | |
| Ki-67 index, (%) | < 0.001b | ||
| Low | 17 (17.5) | 230 (46.9) | |
| High | 80 (82.5) | 260 (53.1) | |
| Histopathology, n (%) | 0.265b | ||
| Invasive ductal carcinoma | 101 (95.3) | 570 (92.2) | |
| Other histology types | 5 (4.7) | 48 (7.8) | |
| Chemotherapy, n (%) | 0.423b | ||
| Anthracycline plus taxane | 77 (72.0) | 433 (68.1) | |
| Other regimens | 30 (28.0) | 203 (31.9) | |
pCR pathological complete response, NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, PIV Pan-immune-inflammation-value, ER estrogen receptor, HER-2 human epidermal growth factor receptor-2.
aMann-Whitney test; bPearson's Chi-squared test.
Data are given as counts (percentages) unless otherwise indicated.
Bold numbers indicate statistical significance.